And obviously the US facing pharma, if you take a Trump call, there is definitely going to be a pressure going forward as such, so that is why we do not like the US focused pharma companies much and we do not have much exposure there, rather no exposure there as such. We are more focused on to domestic pharma. In a diagnostic space, we got the best player, the top player with us.
Sebi approves 3 IPOs of Cosmic PV, Monomark, RKB Global along with NSE
SEBI has approved IPOs for Cosmic PV Power, Monomark Engineering, and RKB Global, alongside the National Stock Exchange’s major public offer. These approvals highlight a
September 4, 2026